Repros: BioCentury Future Leaders in the Biotech Industry Conference (Repros) - Apr 5, 2013 - Anticipated end of Phase 2 meeting with FDA for vaginal uterine fibroids at end of May 2013; Anticipated initiation of P3 trial for vaginal uterine fibroids in Q3 2013; Anticipated initiation of P2 trial of low dose oral formulation for uterine fibroids by Q4 2013
Anticipated FDA event • Anticipated new P2 trial • Anticipated new P3 trial • Anticipated trial initiation date • Uterine Leiomyoma
|